Corbus Pharmaceuticals (CRBP)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals on August 6 and set a price target of $36.00. The company’s shares closed last Friday at $10.17, close to its 52-week low of $5.49.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 14.3% and a 56.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc.
Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $37.38, a 283.8% upside from current levels. In a report issued on August 6, William Blair also reiterated a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
